Afatinib reverses ceritinib resistance (CR) in ALK/ROS1-positive non-small-cell lung cancer cell (NSCLC) via suppression of NRG1 pathway

BACKGROUND: Lung cancer (LC) is the most prevalent malignancy worldwide, and non-small-cell LC (NSCLC) cell is associated with high mortality. As a member of the second generation of anaplastic lymphoma kinase (ALK) suppressors, ceritinib has considerable therapeutic effects for ALK and c-ros oncoge...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hui, Zhang, Qiang, Zhang, Yu, Jia, Bin, Zhang, Bin, Wang, Changli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267764/
https://www.ncbi.nlm.nih.gov/pubmed/30568455
http://dx.doi.org/10.2147/OTT.S173008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267764/
https://www.ncbi.nlm.nih.gov/pubmed/30568455
http://dx.doi.org/10.2147/OTT.S173008

Ejemplares similares